NeuroprotectiveClinical Trials
ARA-290
Also known as: Cibinetide
An EPO-derived peptide that reverses neuropathy without stimulating red blood cell production. The gold standard for small-fiber nerve repair.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~2 minutes
Typical Dose
2–4 mg daily
Administration
Subcutaneous injection
Mechanism of Action
Activates the Innate Repair Receptor (IRR) to promote neural regeneration and halt inflammation without erythropoietic side effects.
Key Research Areas
neuroprotectiveneuropathynerve repairEPO-derived
Frequently Asked Questions
What is ARA-290?▾
An EPO-derived peptide that reverses neuropathy without stimulating red blood cell production. The gold standard for small-fiber nerve repair.
How does ARA-290 work?▾
Activates the Innate Repair Receptor (IRR) to promote neural regeneration and halt inflammation without erythropoietic side effects.
What is the recommended dosage for ARA-290?▾
The typical research dosage is 2–4 mg daily, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of ARA-290?▾
The half-life of ARA-290 is approximately ~2 minutes. This affects dosing frequency and timing in research protocols.
Is ARA-290 FDA approved?▾
ARA-290 is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about ARA-290 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.